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Abstract
Objective: To perform a meta-analysis exploring the correlation between the apparent diffusion coefficient (ADC) and
tumor cellularity in patients.
Materials and Methods: We searched medical and scientific literature databases for studies discussing the correlation
between the ADC and tumor cellularity in patients. Only studies that were published in English or Chinese prior to
November 2012 were considered for inclusion. Summary correlation coefficient (r) values were extracted from each study,
and 95% confidence intervals (CIs) were calculated. Sensitivity and subgroup analyses were performed to investigate
potential heterogeneity.
Results: Of 189 studies, 28 were included in the meta-analysis, comprising 729 patients. The pooled r for all studies was
20.57 (95% CI: 20.62, 20.52), indicating notable heterogeneity (P,0.001). After the sensitivity analysis, two studies were
excluded, and the pooled r was 20.61 (95% CI: 20.66, 20.56) and was not significantly heterogeneous (P= 0.127).
Regarding tumor type subgroup analysis, there were sufficient data to support a strong negative correlation between the
ADC and cellularity for brain tumors. There was no notable evidence of publication bias.
Conclusions: There is a strong negative correlation between the ADC and tumor cellularity in patients, particularly in the
brain. However, larger, prospective studies are warranted to validate these findings in other cancer types.
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Introduction
Diffusion-weighted imaging (DWI), which tracks the micro-
scopic rate of water diffusion within tissues, is a magnetic
resonance imaging (MRI)-based technique that has provided a
new means of tracking tumor progression and response to
treatment. The apparent diffusion coefficient (ADC) typically
replaces the diffusion coefficient as a diffusion index in biological
systems because the latter depends on factors beyond Brownian
motion, such as microcirculation. Because it provides information
about tissue cellularity and the integrity of cell membranes [1],
DWI has benefits over traditional anatomical MRI techniques.
Generally, tumor cell proliferation increases tumor cellularity,
whereas tumor cell apoptosis reduces tumor cellularity. Tumor
cellularity and the shape of the extracellular space affect diffusion.
The diffusivity of water molecules is restricted in environments of
high cellularity because this cellularity reduces the ratio of
extracellular to intracellular space in a given area of tissue [2,3].
Studies conducted in vitro [4,5] and in animal models [6,7] show
that the ADC is inversely correlated with tumor cellularity. The
hypothesis that the ADC is also inversely correlated with tumor
cellularity in patients makes DWI a widely applicable method for
differentiating benign from malignant lesions, monitoring the
treatment response after chemotherapy or radiation, and detecting
recurrent cancer [8]. However, the results of studies attempting to
verify this hypothesis are controversial; certain studies confirmed a
notable negative correlation between the ADC and tumor
cellularity [9–32], whereas other studies presented negative [33–
37] or even inverse results [35,36]. In addition, the sample sizes of
these studies were small.
Therefore, we performed the present meta-analysis to explore
the correlation between the ADC and tumor cellularity in patients




Two independent observers searched the following databases in
September 2012: PubMed, Embase, the Cochrane Library, and
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the China National Knowledge Infrastructure (CNKI). The
databases were searched using the terms ‘‘diffusion-weighted
imaging OR DWI,’’ AND ‘‘cell density OR cellularity OR cell
count OR cell number,’’ AND ‘‘apparent diffusion coefficient OR
ADC.’’ The search was limited to publications written in English
or Chinese to match our translation capacity. We searched
publications published prior to and including November 2012.
The reference lists of all retrieved articles were manually cross-
checked.
Selection of Articles
Articles were selected for inclusion if they met the following
criteria: (a) investigation of the relationship between the ADC and
tumor cellularity; (b) inclusion of patients with tumors, which
could include patients with benign conditions as long as most
patients in the sample had cancer; (c) identification and
characterization of tumors, both benign and malignant by
histopathologic analysis; and (d) publication as a full paper in a
peer-reviewed scientific journal.
The following studies were excluded: (a) multiple reports
published on the same study population (in this case, the
publication that included the most details and/or that was most
recently published was chosen); (b) studies in vitro or in animal
models; (c) studies analyzing the relationship between the ADC
and tumor cellularity with treatment; and (d) review articles,
letters, comments, case reports, and unpublished articles (abstracts
only).
Quality Assessment and Data Extraction
The methodological quality of the included studies was
independently assessed by two observers using the Quality
Assessment of Diagnostic Studies (QUADAS) instrument, a quality
assessment tool specifically developed for systematic reviews of
diagnostic accuracy studies [38,39]. The information extracted
from each publication, in the form of a table, included the
following: authors, the nation of origin, the year of publication, the
number and ages of the patients, b values, techniques, MRI field
strength, vendors, Pearson or Spearman correlation coefficient (r),
and the index used to characterize the ADC (average or minimum
Figure 1. Flowchart of the study selection process.
doi:10.1371/journal.pone.0079008.g001
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expression). Disagreements between the two reviewers were
resolved by a majority opinion after a third reviewer assessed all
involved items.
The correlation coefficients were calculated from a scatter plot
of the ADC and tumor cellularity for cases in which the correlation
coefficients were not reported. First, Engauge Digitizer software
(free software downloaded from http://sourceforge.net) was used
to convert the scatter plots into coordinates. In this way, we
obtained the ADC values and tumor cellularity indirectly. Second,
SPSS software was used to calculate the correlation coefficients.
Because certain variables in the original studies were log-
transformed before analysis, Spearman correlation coefficients
were used for the meta-analyses. Spearman correlation coefficients
are unaffected by monotonic transformations, such as a logarith-
mic transformation. The published Pearson correlation coefficients
were converted into Spearman correlation coefficients [40,41].
The sampling distribution of Spearman correlation coefficients is
problematic because the standard error (SE) depends on the value
of the correlation coefficient. Thus, a Fisher transformation was
used to convert each correlation coefficient into an approximately
normal distribution.
Meta-Analysis
After appropriate conversion, data from the various studies were
combined using random effects meta-analyses [42]. The hetero-
geneity of the r values between studies was determined by
calculating the Q statistic, derived from the chi-square test, and
the inconsistency index (I2) [43,44]. A P-value ,0.05 or an I2
value .50% suggested heterogeneity [45]. If notable heterogene-
ity was detected, a sensitivity analysis was performed for all studies
to further investigate the study heterogeneity.
In a subgroup analysis, studies were stratified by the following:
(a) tumor type, (b) the index of the average ADC (meanADC) or
minimum ADC (minADC), (c) magnetic field strength (1.5 or 3.0
Table 1. Characteristics of the included studies.
Study Year Nation N Tumor Age Design Field Index b valuea rb
Sugahara [26] 1999 Japan 20 brain Adult prospective 1.5 T minADC 1200 20.75
Gupta [20] 2000 USA 18 brain Adult prospective 1.5 T meanADC 940 20.65c
Gauvain [19] 2001 USA 12 brain Children retrospective 1.5 T meanADC 1012 20.67
Kono [25] 2001 Japan 17 brain Adult retrospective 1.5 T meanADC 1000 20.75
2001 Japan 18 brain Adult retrospective 1.5 T meanADC 1000 20.65
Guo A [32] 2002 USA 28 brain Adult retrospective 1.5 T meanADC 1000 20.46
Guo Y [14] 2002 China 47 breast Adult retrospective 1.5 T meanADC 1000 20.51
Chen [10] 2005 China 34 brain Adult retrospective 1.5 T meanADC 1000 20.52
Hayashida [22] 2006 Japan 13 brain Adult retrospective 1.5 T meanADC 1000 20.68
Plank [30] 2007 Austria 8 spinal Adult retrospective 1.5 T meanADC 700 20.64d
Matoba [27] 2007 Japan 9 lung Adult prospective 1.5 T meanADC 577 20.75
Humphries [28] 2007 USA 19 various Children prospective 1.5 T meanADC 1000 20.72c
Zelhof [15] 2008 UK 38 prostate Adult prospective 3.0 T meanADC 500 20.48
Hatakenaka [30] 2008 Japan 124 breast Adult prospective 1.5 T meanADC 1000 20.65c
Manenti [21] 2008 Italy 27 renal Adult retrospective 3.0 T meanADC 500 20.71
Yoshikawa [33] 2008 Japan 27 breast Adult retrospective 1.5 T meanADC 800 0.05
Woodhams [13] 2009 Japan 15 breast Adult retrospective 1.5 T meanADC 1500 20.74
Wang [16] 2009 China 38 prostate Adult retrospective 1.5 T meanADC 500 20.63
Yamashita [31] 2009 Japan 26 brain Adult retrospective 1.5 T minADC 1000 20.69
Gibbs [9] 2009 UK 20 prostate Adult prospective 3.0 T meanADC 500 20.68
Kikuchi [11] 2009 Japan 10 brain Adult retrospective 1.5 T minADC 1000 20.66
Jenkinson [32] 2010 UK 17 brain Adult retrospective 1.5 T both 1000 0.04
Ellingson [18] 2010 USA 17 brain Adult retrospective 1.5 T meanADC 1000 20.88c
Barajas [23] 2010 USA 18 brain Adult retrospective 1.5 T meanADC 1000 20.52
Kyriazi [24] 2010 UK 8 ovarian Adult retrospective 1.5 T meanADC 1050 20.77
2010 UK 7 omental Adult retrospective 1.5 T meanADC 1050 20.72
Wang [31] 2011 USA 18 pancreas Adult retrospective 1.5 T meanADC 600 20.35
Goyal [12] 2012 India 36 renal Adult retrospective 1.5 T meanADC 500 20.31
Doskaliyev [17] 2012 Japan 24 brain Adult retrospective 3.0 T meanADC 1000 20.58
Ginat [29] 2012 USA 18 skull Adult retrospective 1.5 T meanADC 1000 20.58
minADC=measurement of minimum ADC value, meanADC=measurement of average ADC value.
aThe unit of the b value is s/m2.
br = Spearman correlation coefficient.
cr values were calculated based on r2 values.
dThe r value was calculated indirectly from the scatter diagram.
doi:10.1371/journal.pone.0079008.t001
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Figure 2. Methodological quality of the 28 studies.
doi:10.1371/journal.pone.0079008.g002
Figure 3. Forest plots of the summary correlation coefficient (r) with corresponding 95% CIs for the correlation between the ADC
value and tumor cellularity in patients from all eligible studies.
doi:10.1371/journal.pone.0079008.g003
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T), (d) a b value $1000 s/m2 or ,1000 s/m2, (e) design
(prospective or retrospective), (f) patient age (adult or child), (g)
vendors, and (h) the definition of tumor cellularity (cell count, cell
density, or nuclear-to-cytoplasmic ratio).
The results of Begg’s funnel plot (P=0.103) showed no evidence
of notable publication bias (Fig. 6).
The presence of publication bias was visually assessed using a
funnel plot. Statistical manipulation was performed with the
software STATA version 11 (Stata Corporation, College Station,
TX, USA).
The Preferred Reporting Items for Systematic Reviews and
Meta-Analyses statement (PRISMA) [46] was used to improve the
reporting of our research (Fig. 1 and Checklist S1).
Results
The search initially yielded 189 potential literature citations
(Fig. 1). In total, 136 of these studies were immediately excluded
after reviewing the abstracts due to non-relevance (n = 104), tumor
treatment (n = 17), in vitro experiments or animal model use
(n = 12), or publication in languages other than English or Chinese
(n = 3). After reading the full texts of the remaining 53 articles, 24
were excluded due to either a lack of sufficient information to
calculate the correlation coefficients or the use of in vitro or animal
model-based experiments. In the extracted 29 studies, one study
[37] was performed based on a per-point analysis of biopsies,
whereas the other included studies were all based on per-lesion
analyses. As the sample sizes for the data reported on a per-point
basis were too small, the data analysis in this study was performed
only on a per-lesion basis. Finally, 28 published studies (English
language, n= 27; Chinese language, n = 1) fulfilled our inclusion
and exclusion criteria, and a total of 30 experiments were analyzed
because two studies [24,25] included two experiments. The
median number of patients per study was 25.7 (range 7–124),
with a total of 729 patients. The most studied tumor location was
the brain, for which there were 13 studies. The extracted data
from these individual studies are summarized in Table 1. The
quality assessment was moderate in the 28 studies according to the
QUADAS items, and the distribution of the study design is shown
in Fig. 2.
All studies provided data suitable for a meta-analysis. For four
studies [18,20,28,30], the r values were calculated based on the r2
values provided in the papers, and the graphical representations
were examined to determine the sign. For one study [33], the r
value was calculated indirectly from the scatter diagram provided
in the paper.
The pooled r for all studies (Fig. 3) was 20.57 (95% CI: 20.62,
20.52) and exhibited notable heterogeneity (I2 = 53.8%,
P,0.001). After a sensitivity analysis of the overall group of
studies, two studies [35,36] that were considered to be homoge-
neous were excluded. The pooled r after the two homogeneous
studies were excluded (Fig. 4) was 20.61 (95% CI: 20.66, 20.56)
and was not notably heterogeneous (I2 = 23.9%, P= 0.127).
There were no significant differences between all subgroups.
The pooled r values estimated for the different subgroups are
presented in Table 2 and Fig. 5.
Discussion
The aims of our meta-analysis were to explore the correlation
between the ADC and tumor cellularity and to investigate
variations in the methods of clinical application. We excluded
studies performed in vitro and in animal models because many
factors that affect diffusion must be controlled in both. We also
excluded therapeutic studies to simplify our analysis and to
increase its accuracy. Additionally, several effective tumor
treatments have been shown to increase the ADC [47], whereas
others result in a reduction [47]. The tumor ADC has also been
shown to change nonlinearly over the course of treatment [28,48].
Our meta-analysis of published studies showed that there was a
significant negative correlation between the ADC and tumor
cellularity in patients. Our findings provide evidence that DWI
can be used as a biomarker for tumor cellularity. Compared with
benign lesions, malignant tumors have larger nuclei, richer stroma,
and higher cell counts, which lead to greater cellularity. By
measuring the ADC, DWI can be used to distinguish benign from
malignant tumors. In general, any effective pharmacologic or
radioactive treatment that causes necrosis or cellular lysis will lead
to less cellularity. A decrease in the number of tumor cells in
response to treatment obviously precedes size change; therefore,
DWI may be an early biomarker for predicting treatment
outcomes, monitoring the early treatment response, and detecting
recurrent cancer.
There was noticeable heterogeneity in all of the included
studies, so we investigated the sources of this heterogeneity. A
sensitivity analysis identified two studies that caused heterogeneity,
which were excluded. One of the two studies [35] focused on
oligodendroglial tumors because oligodendroglial tumors with 1p/
19q loss are more likely to have a low ADC than tumors with
intact 1p/19q. In the other study [36], both invasive ductal
carcinoma and noninvasive ductal carcinoma were analyzed
together, and the authors speculated that the ADC may be
affected not only by cancer cellularity but also by histological type.
Generally, the values for diffusion found in most tumors have been
attributed to the tumors’ cellular density; however, this concept
remains controversial because diffusivity is influenced by other
histological characteristics, such as fibrosis, the shape and size of
the intercellular spaces, and glandular structure (as in well-
differentiated adenocarcinomas). We also performed a subgroup
Table 2. Sensitivity estimates for each subgroup.
Subgroup
No. of
experiments r (95% CI) I2 P value
Definitiona
Cell count 3 20.61(20.78, 20.45) 38.5% 0.197
Cell density 13 20.62(20.70, 20.54) 40.4% 0.064
N/C ratio 12 20.60(20.67, 20.53) 0.0% 0.450
Vendora
GE 13 20.55(20.63, 20.47) 63.5% 0.001
Philips 2 20.70(20.89, 20.50) 0.0% 0.776
Siemens 9 20.65(20.73, 20.58) 0.0% 0.865
No mention 4 20.66(20.79, 20.58) 0.0% 0.702
Tumor typea
Brain 13 20.62(20.71, 20.54) 41.7% 0.057
Prostate 3 20.58(20.72, 20.44) 0.0% 0.529
Breast 3 20.62(20.71, 20.53) 3.1% 0.356
Renal 2 20.48(20.67, 20.29) 84.4% 0.011
Otherb 7 20.61(20.75, 20.48) 0.0% 0.731
N/C ratio = nuclear-to-cytoplasmic ratio.
aThere are no significant differences between the subgroups of tumors.
bIncludes tumors of the lung, ovaries, omentum, skull, pancreas, spine, and
various other locations.
doi:10.1371/journal.pone.0079008.t002
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analysis based on the histological type. The result showed no
notable variation between the subgroups based on tumor type.
However, we observed that the correlation between the ADC and
tumor cellularity differed between histological types, with corre-
lation coefficients ranging from 20.79 (liver tumor, n= 1) to
20.35 (pancreatic endocrine tumor, n= 1). We believe that
sample sizes large enough for comparison could be a source of
heterogeneity.
Other sources of heterogeneity may be present, including the
technical characteristics of the DWI scanning and measurements
that were compared between the reviewed studies. Indeed, the
implementation of scanning protocols and measurement by
different companies varies significantly. Moreover, there is
divergent nomenclature among the vendors for the implementa-
tion of DWI [8]. It is also clear that variations in the b value exist
and that there is no consensus on the measurement index of the
ADC or the magnetic field strengths. Our subgroup analysis
indicated that none of these factors contributed to the observed
heterogeneity. The validations among vendors and the magnetic
field strengths (1.5 and 3.0 T) were nearly identical. However, the
application of the index minADC and a high b value (b value
$1000 s/m2) may be more related to tumor cellularity. We
recommend specific experiments to further investigate variations
in these methods. If confirmed, our finding would provide
evidence for establishing clinical DWI acquisition and analysis
guidelines.
Certain inherent limitations existed in our study design and
should be considered when interpreting our results. First, the
number of patients in several of the included studies was relatively
small, and the number of patients included for each organ was
relatively small, which may reduce the strength of the conclusions
in this paper. Second, our meta-analysis was based only on
published studies, which tend to report positive or significant
results; studies with insignificant or negative results are often
rejected or are not submitted. This feature may have led to a
publication bias, which tends to overestimate results. However, it is
likely that the quality of the data reported in articles accepted for
publication in peer-reviewed journals is superior to the quality of
unpublished data [49]. In addition, this review was restricted to
articles published in English or Chinese because other languages,
such as Cabada [50], could not be translated by the study authors,
which may have introduced bias.
In conclusion, despite the limitations of our meta-analysis, all
currently available evidence supports a strong negative correlation
between the ADC and tumor cellularity in patients, particularly in
brain, prostate, breast, and renal tumors. However, larger,
prospective studies are warranted to validate these findings in
other cancer types. Future validation studies of DWI will likely
Figure 4. Forest plots of the pooled r with corresponding 95% CIs after two studies were excluded following a sensitivity analysis
and forest plots of the subgroup analysis based on tumor type.
doi:10.1371/journal.pone.0079008.g004
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benefit from the following: (a) the application of the index to both
the minADC and the meanADC, (b) the inclusion of high and low
b values, and (c) the establishment of specific guidelines for
performing and analyzing standard clinical DWI scans.
Figure 5. The pooled r with corresponding 95% CIs for the subgroup analysis based on magnetic field strength, the index of the
ADC value, the b value, age, and design.
doi:10.1371/journal.pone.0079008.g005
Figure 6. The funnel plot of the publication bias. The result is suggestive of an indistinctive small study bias (P= 0.103).
doi:10.1371/journal.pone.0079008.g006
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